Core Insights - AbbVie reported revenue of $15.78 billion for the quarter ended September 2025, reflecting a 9.1% increase year-over-year and surpassing the Zacks Consensus Estimate of $15.59 billion by 1.2% [1] - The company's EPS was $1.86, down from $3.00 in the same quarter last year, but exceeded the consensus estimate of $1.77 by 5.08% [1] Revenue Performance by Segment - Oncology (Elahere) generated $170 million, below the average estimate of $199.05 million, but showed a year-over-year increase of 22.3% [4] - Creon (US) reported $368 million, exceeding the estimate of $350.08 million, with an 8.9% year-over-year growth [4] - Rinvoq (International) achieved $625 million, surpassing the estimate of $606.08 million, marking a significant 40.8% increase year-over-year [4] - Humira (US) revenue was $619 million, significantly below the estimate of $764.72 million, reflecting a drastic year-over-year decline of 64.9% [4] - Neuroscience total revenue reached $2.84 billion, exceeding the estimate of $2.74 billion, with a year-over-year increase of 20.2% [4] - Vraylar total revenue was $934 million, slightly below the estimate of $946.65 million, showing a year-over-year growth of 6.7% [4] - Immunology total revenue was $7.89 billion, in line with the estimate of $7.88 billion, representing an 11.9% year-over-year increase [4] - Rinvoq total revenue was $2.18 billion, slightly above the estimate of $2.16 billion, with a year-over-year growth of 35.3% [4] - Botox Therapeutic total revenue was $985 million, exceeding the estimate of $922.4 million, with a year-over-year increase of 16.2% [4] - Juvederm Collection total revenue was $253 million, slightly below the estimate of $257.9 million, reflecting a year-over-year decline of 1.9% [4] - Botox Cosmetic total revenue was $637 million, below the estimate of $686.58 million, with a year-over-year decrease of 5.1% [4] - Imbruvica revenue was $706 million, slightly below the estimate of $708.25 million, showing a year-over-year decline of 14.7% [4] Stock Performance - AbbVie shares have returned -3.5% over the past month, contrasting with the Zacks S&P 500 composite's +2.1% change, indicating underperformance relative to the broader market [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the market in the near term [3]

Core Viewpoint - Analysts project AbbVie (ABBV) will report quarterly earnings of $2.40 per share, a 3.9% increase year over year, with revenues expected to reach $12.91 billion, reflecting a 4.8% increase from the same quarter last year [1]. Earnings Estimates - The consensus EPS estimate has been revised downward by 0.8% over the past 30 days, indicating a collective reassessment by analysts [2]. - Revisions to earnings estimates are crucial for predicting investor actions, as empirical research shows a strong correlation between earnings estimate trends and short-term stock performance [3]. Revenue Projections - Analysts estimate 'Net Revenue- Botox Cosmetic- Total' at $576.62 million, down 8.9% year over year [5]. - 'Net Revenue- Imbruvica' is projected to be $676.15 million, reflecting a decrease of 19.3% from the prior-year quarter [5]. - 'Net Revenue- Eye Care- Total' is expected to be $531.41 million, indicating a slight decline of 1.2% [5]. - 'Net Revenue- Juvederm Collection- Total' is forecasted at $253.59 million, down 14.6% from the year-ago quarter [6]. - 'Net Revenue- Creon- US' is estimated at $267.00 million, a decrease of 6.3% year over year [6]. - 'Net Revenue- Rinvoq- International' is projected to reach $504.96 million, an increase of 37.2% from the prior-year quarter [6]. - 'Net Revenue- Rinvoq- US' is expected to be $1.09 billion, reflecting a significant increase of 50.2% year over year [7]. - 'Net Revenue- Humira- International' is estimated at $422.30 million, down 15.4% from the prior-year quarter [7]. - 'Net Revenue- Humira- US' is projected at $898.84 million, indicating a substantial decline of 49.3% year over year [7]. - 'Net Revenue- Immunology- Skyrizi- International' is expected to be $507.22 million, up 44.1% year over year [8]. - 'Net Revenue- Immunology- Skyrizi- US' is projected at $2.69 billion, reflecting a 62.3% increase year over year [8]. - The consensus estimate for 'Geographic Revenues- International' stands at $3.42 billion, indicating a 4.5% increase from the prior-year quarter [9]. Stock Performance - Over the past month, AbbVie shares have returned -18.7%, compared to the Zacks S&P 500 composite's -8.9% change [9].